Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

New England Journal of Medicine

Volumn 349, Issue 11, 2003, Pages 1036-1046

  Martínez, Esteban ^a,n   Arnaiz, Juan A ^a   Podzamczer, Daniel ^o   Dalmau, David ^b   Ribera, Esteban ^c   Domingo, Pere ^d   Knobel, Hernando ^e   Riera, Melcior ^f   Pedrol, Enric ^g   Force, Lluis ^h   Llibre, Josep M ⁱ   Segura, Ferran ^j   Richart, Cristóbal ^k   Cortés, Cristina ^o   Javaloyas, Manuel ^l   Aranda, Miquel ^m   Cruceta, Ana ^a   De Lazzari, Elisa ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^h HOSPITAL DE MATARÓ   (Spain)

ⁱ Hospital Sant Jaume de Calella   (Spain)

^j HOSPITAL DE SABADELL   (Spain)

^k HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^l HOSPITAL DE VILADECANS   (Spain)

^m HOSPITAL DE TERRASSA   (Spain)

ⁿ UNIVERSITY OF BARCELONA   (Spain)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; OXAZINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT FAILURE; TREATMENT OUTCOME; BLOOD; DRUG COMBINATION; GENETICS; MIDDLE AGED; MORTALITY;

ADULT; AGED; DIDEOXYNUCLEOSIDES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 0042387870     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021589     Document Type: Article

References (41)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
3. Rubio R, Berenguer J, Miro JM, et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enferm Infecc Microbiol Clin 2002;20:244-303.
4. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
5. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
6. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
7. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.
8. Pujol RM, Domingo P, Matías-Guiu X, et al. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol 2000;42:193-8.
9. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
10. Van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99.
11. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients: the COMBINE study. Antivir Ther 2002;7:81-90.
12. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
13. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD and Efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through week 24 (AI424-034). In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 27-30, 2002. Washington, D.C.: American Society for Microbiology, 2002:11-1076. abstract.
14. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviralnaive HIV-infected adults: a randomized equivalence trial. JAMA 2001;9:1155-63.
15. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
16. Dieleman JP, Gyssens IC, Sturkenboom MJCM, Niesters HGM, van der Ende ME. Substituting nevirapine for protease inhibitors because of intolerance. AIDS 1999;13:1423-4.
17. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
18. Raffi F, Bonnet B, Ferré V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000;31:1274-8.
19. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36.
20. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
21. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
22. Rey D, Schmitt MP, Partisani M, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001;27:459-62.
23. Knechten H, Stürner KH, Höhn C, Braun P. Switch to efavirenz in a protease inhibitor-containing regimen. HIV Clin Trials 2001;2:200-4.
24. Hirschel B, Flepp M, Bucher HC, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002;16:381-5.
25. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients wtih undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
26. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000;132:306-11.
27. Murphy RL, Smith WJ. Switch studies: a review. HIV Med 2002;3:146-55.
28. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002;35:1219-30.
29. Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 12-month results of a randomized study (LIPNEFA). In: Program and abstracts of the 14th International AIDS Conference, Barcelona, Spain, July 7-12, 2002: B7. abstract.
30. AIDS Clinical Trials Group. Table for grading severity of adult adverse experiences. August 1992. (Accessed June 30, 2003, at http://aactg.s-3.com/members/adulttox.htm.)
31. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
32. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8.
33. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998;339:1269-76.
34. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34:483-6.
35. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-40.
36. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-95.
37. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002;16:53-61.
38. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, with stavudine and lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003:176. abstract.
39. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
40. Masquelier B, Neau D, Chêne G, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2001;28:309-12.
41. Dieleman JP, Sturkenboom MCJM, Wit FW, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002;185:1261-8.